Accent

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Carizma Motors Expands Pre-Owned Inventory with High-Quality Hyundai Vehicles

Retrieved on: 
Friday, October 20, 2023
Hyundai Accent, Accent, Hyundai, Multimedia, Automotive industry, Online shopping

LUBBOCK, Texas, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Carizma Motors is excited to announce the latest addition of used Hyundai vehicles to its pre-owned inventory. With this development, the dealership continues to cater to the discerning tastes of automotive enthusiasts. A trusted name in the Lubbock automotive market, they aim to provide buyers with another compelling used vehicle option that aligns with their desires for value and performance.    

Key Points: 
  • Customers can now purchase top-notch used Hyundai models from Carizma Motors in Lubbock, Texas.
  • LUBBOCK, Texas, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Carizma Motors is excited to announce the latest addition of used Hyundai vehicles to its pre-owned inventory.
  • Carizma Motors is proud to offer well-maintained Hyundai vehicles, recognizing the demand for quality pre-owned options in the area.
  • Prospective buyers are encouraged to visit Carizma Motors and explore the used Hyundai models.

Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium

Retrieved on: 
Tuesday, October 10, 2023
PKR, ADAR1, XRN1, Cell death, RNA, Cell, Glomus tumor, DHX9, XRN2, Cancer, Therapy, Maintenance, MDA5, Neoplasm, Immortalised cell line, Messenger, Accent, Patient, Poster, Pharmaceutical industry, Vaccine

LEXINGTON, Mass., Oct. 10, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced it will present data unveiling a novel, previously undisclosed program in two poster presentations at the 35th AACR-NCI-EORTC Symposium held October 11-15, 2023 in Boston, Massachusetts. The company will also present data supporting development of its ADAR1 and DHX9 programs in two additional poster presentations.

Key Points: 
  • The company will also present data supporting development of its ADAR1 and DHX9 programs in two additional poster presentations.
  • Two of the company's presentations at the meeting describe the preclinical validation of XRN1 as an oncology target and the subsequent characterization of selective inhibitors of XRN1.
  • Accent has identified novel, potent, and selective allosteric inhibitors that bind XRN1 with nanomolar target affinity without binding to XRN2.
  • Accent will also present its innovative suite of in vitro and cellular assays that enable identification of small molecule inhibitors of ADAR1.

Thompson Law Offices Sues Hyundai Motor America for Not Installing Industry Standard Anti-Theft Devices in Cars, Putting Customers at Higher Risk of Violent Crimes

Retrieved on: 
Tuesday, September 19, 2023
Legal, Professional Services, Hyundai i30, P.C, Theft, Hyundai Elantra, Forte, Sonata, Orange County, Superior court, USB, Fatality, Accent, Federal Motor Vehicle Safety Standards, Hyundai Genesis Coupe, Optima, Milk, Risk, SUV, Kia Sportage, Hyundai Veloster, Social media, Safety, Automotive industry, K5, TikTok, Kia, Hyundai

against Hyundai Motor America, Inc. for its failure to equip her Hyundai Elantra with an industry standard anti-theft ignition immobilizer, making it easier to steal, and her the target of a violent crime.

Key Points: 
  • against Hyundai Motor America, Inc. for its failure to equip her Hyundai Elantra with an industry standard anti-theft ignition immobilizer, making it easier to steal, and her the target of a violent crime.
  • As a result, Lawton was shot in the chest and nearly killed while thieves were attempting to steal her car.
  • “When Hyundai chose to gamble with safety, it bet the lives of Americans,” Thompson added.
  • Hyundai and Kia owners can learn more by visiting www.violentcartheft.com or calling (650) 513-6111.

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 21, 2023
Molecule, Fulcrum, Amgen, American Chemical Society, Drug development, University, Weill Cornell Medicine, Marie Curie, Delta TechOps, Organic chemistry, CMC, Health, Cancer, Program management, Mentorship, Genentech, Tango, Dana–Farber Cancer Institute, Development, National Cancer Institute, Ribociclib, Johns Hopkins University, Novartis, Patient, Ruth, DHX9, MSI-H, Boston College, Therapy, IND, RWTH, Massachusetts Institute of Technology, Pharmaceutical industry, Accent, Chemistry, Sanofi, Research

LEXINGTON, Mass., Sept. 21, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the appointments of Jason Sager, M.D., as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

Key Points: 
  • "Our dedication to fortifying our team underscores the remarkable progress we've achieved as Accent advances its lead programs towards the clinic," said Shakti Narayan, Chief Executive Officer of Accent.
  • Together, Jason, Steven, and Stuart's combined experience will be immensely valuable as Accent moves towards becoming a clinical-stage company and bringing novel therapies to patients."
  • These key executive hires enhance Accent's positioning to potentially advance two investigational programs into the clinic.
  • Accent is also on track to begin IND-enabling studies for a second undisclosed program by the end of 2023.

Alma welcomes the iconic Hollywood superstar, Kate Hudson as its new Global Brand Ambassador

Retrieved on: 
Wednesday, September 6, 2023
Opus, Hair removal, Partnership, Skin, LMNT, Elective surgery, Almost Famous, Snail, Kate Hudson, Kate, Accent, Harmony, Beauty, Fad, How to Lose a Guy in 10 Days, Glass onion, Laser, Netflix, Empowerment, Global Brands Group, Social media, Primex Tower, Fashion design, Film industry, Soprano, Eminem

CAESAREA, Israel, Sept. 6, 2023 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and global leader in energy-based medical and aesthetic solutions, proudly announced Kate Hudson as their new Global Brand Ambassador.

Key Points: 
  • CAESAREA, Israel, Sept. 6, 2023 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and global leader in energy-based medical and aesthetic solutions, proudly announced Kate Hudson as their new Global Brand Ambassador.
  • Hudson, an award-winning actress, successful entrepreneur, and inspirational figure in beauty, aesthetics, and well-being, brings her influential presence to the forefront of Alma's mission.
  • "We are thrilled to welcome Hollywood star Kate Hudson as our new Global Brand Ambassador," said Lior Dayan, Alma CEO.
  • "Partnering with Alma feels incredibly natural because we share the same passion," said Kate Hudson.

Alma welcomes the iconic Hollywood superstar, Kate Hudson as its new Global Brand Ambassador

Retrieved on: 
Wednesday, September 6, 2023
Opus, Hair removal, Partnership, Skin, LMNT, Elective surgery, Almost Famous, Snail, Kate Hudson, Kate, Accent, Harmony, Beauty, Fad, How to Lose a Guy in 10 Days, Glass onion, Laser, Netflix, Empowerment, Global Brands Group, Social media, Primex Tower, Fashion design, Film industry, Soprano, Eminem

CAESAREA, Israel, Sept. 6, 2023 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and global leader in energy-based medical and aesthetic solutions, proudly announced Kate Hudson as their new Global Brand Ambassador.

Key Points: 
  • CAESAREA, Israel, Sept. 6, 2023 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and global leader in energy-based medical and aesthetic solutions, proudly announced Kate Hudson as their new Global Brand Ambassador.
  • Hudson, an award-winning actress, successful entrepreneur, and inspirational figure in beauty, aesthetics, and well-being, brings her influential presence to the forefront of Alma's mission.
  • "We are thrilled to welcome Hollywood star Kate Hudson as our new Global Brand Ambassador," said Lior Dayan, Alma CEO.
  • "Partnering with Alma feels incredibly natural because we share the same passion," said Kate Hudson.

elemense Evolves: The New "Kohgou Hinoki Plate Diffuser"

Retrieved on: 
Thursday, August 17, 2023
Travel, Chamaecyparis obtusa, Life, Accent, Element, Wood, Market, Collection, Nature, Water, LOS, Relaxation, Furniture

LOS ANGELES, Aug. 17, 2023 /PRNewswire/ -- As elemense takes course to be well-known and sought after in high-end home fragrance stores in the U.S and Japan, it expands its offerings with its latest diffuser products. It is a two-piece white porcelain container called kohgou (ko-go), designed to hold a piece of the sacred Hinoki wood plate inside.

Key Points: 
  • It is a two-piece white porcelain container called kohgou (ko-go), designed to hold a piece of the sacred Hinoki wood plate inside.
  • To enjoy kohgou, simply apply a few drops of the elemense diffuser oil (five fragrances available, sold separately) onto the Hinoki plate and allow the soft aroma to spread.
  • The Hinoki Plate diffuser refill is also available so that different diffuser oil can be used for the same kohgoh container— simply swap the diffuser plate inside it to enjoy more than one fragrance.
  • The size of the Hinoki Plate is approximately     2 ¾  x ¼ x 1 ¾ (in).

Apollo Impact to Acquire Accent Family of Companies, a Leading Value-Added Distributor and Manufacturer of Baling Wires and Equipment Servicing the Recycling and Waste Management Industries

Retrieved on: 
Monday, August 7, 2023
PwC, APO, The Bridgespan Group, Latham & Watkins, Recycling, Acquisition, Sun Belt, Sims, Growth, Paul, Weiss, Rifkind, Wharton & Garrison, Transport, NYSE, Renewable energy, Accent

Accent is a leader in the distribution and manufacturing of baling wires and wire-tier machines, which are core products used in the recycling and waste industries in the U.S., Canada, and the U.K.

Key Points: 
  • Accent is a leader in the distribution and manufacturing of baling wires and wire-tier machines, which are core products used in the recycling and waste industries in the U.S., Canada, and the U.K.
  • In addition, complementing its core recycling solutions business, Accent Building Materials is a regional wholesale distributor of building materials serving customers across the Sun Belt in the U.S.
  • Existing investor Crossplane Capital (“Crossplane”) partnered with Accent’s founders, the Sims family, in 2019 to acquire a controlling interest in Accent.
  • Apollo was advised by Paul, Weiss, Rifkind, Wharton & Garrison LLP, Latham & Watkins LLP, PwC, and the Bridgespan Group.

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, April 6, 2023
Maintenance, Colorectal cancer, AACR, American Association for Cancer Research, Accent, Therapy, CRC, RNA, MSI, DHX9, Vaccine

LEXINGTON, Mass., April 6, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company developing breakthrough, oncology-focused small molecule therapies that target RNA-modifying proteins, today announced an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Key Points: 
  • LEXINGTON, Mass., April 6, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company developing breakthrough, oncology-focused small molecule therapies that target RNA-modifying proteins, today announced an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
  • The oral presentation will provide rationale to support targeting inhibitors of DHX9, an RNA helicase which has been reported to play important roles in replication, transcription, translation, RNA processing and maintenance of genomic stability, as a novel therapeutic modality in microsatellite instable (MSI) colorectal cancer (CRC).
  • The presentation will further describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.
  • The presentation will be available on the Accent website following the meeting.